On the basis of the DMN subserving dreaming, being impaired in APOE ε4 carriers, and showing pre-clinical AD-related neuropathology, we hypothesized that dream recall will be reduced in cognitively healthy older adults who are APOE ε4 carriers or positive for AD biomarkers, or who show future cognitive decline including dementia. The gene discussed is APOE; the disease is Alzheimer disease.